SG11202105911PA - Usp19 inhibitors for use in therapy - Google Patents
Usp19 inhibitors for use in therapyInfo
- Publication number
- SG11202105911PA SG11202105911PA SG11202105911PA SG11202105911PA SG11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA
- Authority
- SG
- Singapore
- Prior art keywords
- therapy
- usp19
- inhibitors
- usp19 inhibitors
- Prior art date
Links
- 101150006083 USP19 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1819936.4A GB201819936D0 (en) | 2018-12-06 | 2018-12-06 | Therapeutic methods |
| GBGB1904341.3A GB201904341D0 (en) | 2019-03-28 | 2019-03-28 | Therapeutic methods |
| PCT/GB2019/053456 WO2020115500A1 (en) | 2018-12-06 | 2019-12-06 | Usp19 inhibitors for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105911PA true SG11202105911PA (en) | 2021-07-29 |
Family
ID=68887434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105911PA SG11202105911PA (en) | 2018-12-06 | 2019-12-06 | Usp19 inhibitors for use in therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220016115A1 (en) |
| EP (1) | EP3890737B1 (en) |
| JP (1) | JP2022510700A (en) |
| KR (1) | KR20210100127A (en) |
| CN (1) | CN113395965A (en) |
| AU (1) | AU2019393161A1 (en) |
| BR (1) | BR112021010645A2 (en) |
| CA (1) | CA3121422A1 (en) |
| IL (1) | IL283687A (en) |
| MX (1) | MX2021006542A (en) |
| SG (1) | SG11202105911PA (en) |
| WO (1) | WO2020115500A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020267757B2 (en) * | 2019-05-06 | 2025-03-27 | Valo Health, Inc. | Inhibiting USP19 |
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202311227D0 (en) | 2023-07-21 | 2023-09-06 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| CL2008003595A1 (en) | 2007-12-03 | 2009-11-20 | Takeda Pharmaceuticals Co | Nitrogen heterocyclic compounds, tachykinin receptor antagonists; pharmaceutical agent comprising the compound; and use in the prophylaxis or treatment of a lower urinary tract disease, a gastrointestinal disease, or a disease of the central nervous system. |
| CN104174021A (en) * | 2013-05-22 | 2014-12-03 | 复旦大学附属华山医院 | Application of proteasome inhibitors in preparation of medicine for curing chronic lower-grade inflammation diseases |
| TWI698436B (en) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2019067503A1 (en) * | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | Novel usp7 inhibitors for treating multiple myeloma |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-06 KR KR1020217019978A patent/KR20210100127A/en not_active Withdrawn
- 2019-12-06 WO PCT/GB2019/053456 patent/WO2020115500A1/en not_active Ceased
- 2019-12-06 EP EP19821175.7A patent/EP3890737B1/en active Active
- 2019-12-06 BR BR112021010645-6A patent/BR112021010645A2/en not_active IP Right Cessation
- 2019-12-06 SG SG11202105911PA patent/SG11202105911PA/en unknown
- 2019-12-06 AU AU2019393161A patent/AU2019393161A1/en not_active Abandoned
- 2019-12-06 JP JP2021532119A patent/JP2022510700A/en active Pending
- 2019-12-06 US US17/299,971 patent/US20220016115A1/en not_active Abandoned
- 2019-12-06 MX MX2021006542A patent/MX2021006542A/en unknown
- 2019-12-06 CA CA3121422A patent/CA3121422A1/en active Pending
- 2019-12-06 CN CN201980091404.7A patent/CN113395965A/en active Pending
-
2021
- 2021-06-03 IL IL283687A patent/IL283687A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3890737A1 (en) | 2021-10-13 |
| JP2022510700A (en) | 2022-01-27 |
| IL283687A (en) | 2021-07-29 |
| AU2019393161A1 (en) | 2021-06-17 |
| US20220016115A1 (en) | 2022-01-20 |
| MX2021006542A (en) | 2021-07-07 |
| CA3121422A1 (en) | 2020-06-11 |
| KR20210100127A (en) | 2021-08-13 |
| CN113395965A (en) | 2021-09-14 |
| WO2020115500A1 (en) | 2020-06-11 |
| BR112021010645A2 (en) | 2021-08-17 |
| EP3890737B1 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL282663A (en) | Bt1718 for use in treating cancer | |
| IL269462A (en) | Mdm2 inhibitors and therapeutic methods using the same | |
| IL251618A0 (en) | Combination therapy comprising ox40 binding agonists and tigit inhibitors | |
| IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
| PL3256218T3 (en) | A kdm1a inhibitor and its use in therapy | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| EP3313514A4 (en) | Positioning device for use in therapeutic treatment | |
| LT4119569T (en) | Conjugated antisense compounds for use in therapy | |
| IL284053A (en) | Novel compounds and their use in therapy | |
| IL288728A (en) | Anti-sortilin antibodies for use in therapy | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| IL283687A (en) | Usp19 inhibitors for use in therapy | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL284981A (en) | Semaphorin-4d antagonists for use in cancer therapy | |
| ZA202000904B (en) | Mpo inhibitors for use in medicine | |
| GB201821147D0 (en) | Mirna for use in therapy | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| GB201615844D0 (en) | Agents for use in therapy | |
| HK40052012A (en) | Usp19 inhibitors for use in therapy | |
| GB201908884D0 (en) | Inhibitors and use | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
| GB201503053D0 (en) | Apparatus for use in magnetic hyperthermia treatments |